Robert Kronemeyer

Challenges with overlaps in diagnosis and classification based on rosacea’s 4 subtypes are creating a new focus on features of the condition in each patient. A pipeline of new drugs awaiting FDA approvals could further expand options.

Lack of specific phenotypes complicates verification.

Novel inhibitor of the 26S proteasome was found to be safe, well-tolerated, and effective in reducing inflammatory lesions and erythema in patients with rosacea.

Patients with anxiety/depression and psoriatic arthritis (PsA) are much less likely to achieve long-term remission. Mental health comorbidities need to be a more important part of PsA treatment.

American Academy of Dermatology’s updated guidelines on acne will cover dermatology’s hottest issues, from dosing and monitoring established medications to exploring new antibiotics and addressing antibiotic stewardship.

Physicians must learn how to tailor treatments and assess skin of color risk to best serve the POC patient population. Doing so will deliver positive outcomes and drive patient satisfaction.

Patients of color make up a growing market for aesthetic dermatology. Physicians must learn how to tailor treatments and assess skin of color risk to best serve this emerging patient population. Doing so will deliver positive outcomes and drive patient satisfaction.

Phase 2 data adds to evidence showing efficacy of JAK inhibitors for treating alopecia areata, for which there are no FDA-approved treatments.

Trichometric analysis helps evaluate whether treatment is working for patients experiencing hair loss and what adjustments need to be made to the regimen.